{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:14:19Z","timestamp":1784747659110,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Global Medical Genetics"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1055\/s-0044-1791734","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T20:46:28Z","timestamp":1730234788000},"page":"358-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Role of the Plasminogen Activator Inhibitor 1 (PAI1) in Ovarian Cancer: Mechanisms and Therapeutic Implications"],"prefix":"10.1016","volume":"11","author":[{"given":"Sneha Grace","family":"Mathews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B. Devi","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lavanya M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nandini K.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Murali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Andrea Mary F.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1055\/s-0044-1791734_bib1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J Womens Health"},{"issue":"02","key":"10.1055\/s-0044-1791734_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","article-title":"Ovarian cancer","volume":"60","author":"Colombo","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"04","key":"10.1055\/s-0044-1791734_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chin Clin Oncol"},{"issue":"02","key":"10.1055\/s-0044-1791734_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/15384047.2014.1001271","article-title":"Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer","volume":"16","author":"Mashiko","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1055\/s-0044-1791734_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211037813","article-title":"PAI-1 polymorphisms have significant associations with cancer risk, especially feminine cancer","volume":"20","author":"Wang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1055\/s-0044-1791734_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/858293","article-title":"Functional stability of plasminogen activator inhibitor-1","volume":"2014","author":"Yasar Yildiz","year":"2014","journal-title":"ScientificWorld-Journal"},{"key":"10.1055\/s-0044-1791734_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.622473","article-title":"Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition","volume":"7","author":"Sillen","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"19","key":"10.1055\/s-0044-1791734_bib8","doi-asserted-by":"crossref","first-page":"9129","DOI":"10.1016\/S0021-9258(19)76517-X","article-title":"Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences","volume":"263","author":"Bosma","year":"1988","journal-title":"J Biol Chem"},{"issue":"03","key":"10.1055\/s-0044-1791734_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10555-019-09806-4","article-title":"The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding","volume":"38","author":"Kubala","year":"2019","journal-title":"Cancer Metastasis Rev"},{"issue":"05","key":"10.1055\/s-0044-1791734_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052721","article-title":"A narrative review on plasminogen activator inhibitor-1 and its (patho)physiological role: to target or not to target?","volume":"22","author":"Sillen","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"32","key":"10.1055\/s-0044-1791734_bib11","doi-asserted-by":"crossref","first-page":"24665","DOI":"10.1074\/jbc.M109.091256","article-title":"Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt\/beta-catenin signaling","volume":"285","author":"He","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1055\/s-0044-1791734_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1150991","article-title":"Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy","volume":"11","author":"Kelly","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"10.1055\/s-0044-1791734_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.canlet.2018.10.027","article-title":"PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination","volume":"442","author":"Peng","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1055\/s-0044-1791734_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biopha.2018.05.119","article-title":"Plasminogen activator inhibitor-1 in cancer research","volume":"105","author":"Li","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"08","key":"10.1055\/s-0044-1791734_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081651","article-title":"Role of plasminogen activator inhibitor type 1 in pathologies of female reproductive diseases","volume":"18","author":"Ye","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1055\/s-0044-1791734_bib16","first-page":"6","article-title":"What is the impact of plasminogen activator inhibitor type 1 (PAI-1) gene polymorphism on gynecological malignancies: a retrospective study","volume":"v1","author":"Li","year":"2023","journal-title":"Research Square"},{"issue":"06","key":"10.1055\/s-0044-1791734_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005918","article-title":"Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer","volume":"4","author":"Bentov","year":"2009","journal-title":"PLoS One"},{"issue":"06","key":"10.1055\/s-0044-1791734_bib18","first-page":"5995","article-title":"The core genes involved in the promotion of depression in patients with ovarian cancer","volume":"18","author":"Yi","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1055\/s-0044-1791734_bib19","doi-asserted-by":"crossref","unstructured":"Czekay RF, Simone TM, Higgins PJ. SerpinE1. Springer eBooks; Published online January 1, 2016:1\u201311","DOI":"10.1007\/978-1-4614-6438-9_101828-1"},{"issue":"08","key":"10.1055\/s-0044-1791734_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/cancers10080251","article-title":"The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer","volume":"10","author":"Savant","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1055\/s-0044-1791734_bib21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1541-7786.MCR-23-0015","article-title":"Continuous administration of anti-VEGFA antibody upregulates PAI-1 secretion from ovarian cancer cells via miR-143-3p downregulation","volume":"21","author":"Yagi","year":"2023","journal-title":"Mol Cancer Res"},{"issue":"02","key":"10.1055\/s-0044-1791734_bib22","first-page":"151","article-title":"Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications","volume":"27","author":"Kurman","year":"2008","journal-title":"Int J Gynecol Pathol"},{"issue":"7553","key":"10.1055\/s-0044-1791734_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"52","key":"10.1055\/s-0044-1791734_bib24","doi-asserted-by":"crossref","first-page":"89887","DOI":"10.18632\/oncotarget.20834","article-title":"Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination","volume":"8","author":"Nakatsuka","year":"2017","journal-title":"Oncotarget"},{"issue":"02","key":"10.1055\/s-0044-1791734_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ijc.23491","article-title":"HMGA2 gene is a promising target for ovarian cancer silencing therapy","volume":"123","author":"Malek","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1055\/s-0044-1791734_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2019.12.019","article-title":"Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment","volume":"318","author":"Kim","year":"2020","journal-title":"J Control Release"},{"issue":"12","key":"10.1055\/s-0044-1791734_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126532","article-title":"Ovarian cancer immunotherapy and personalized medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1055\/s-0044-1791734_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-8722-3-7","article-title":"Ovarian cancer immunotherapy: opportunities, progresses and challenges","volume":"3","author":"Liu","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"01","key":"10.1055\/s-0044-1791734_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/proteomes12010008","article-title":"Biomarkers in ovarian cancer: towards personalized medicine","volume":"12","author":"L\u00f3pez-Portugu\u00e9s","year":"2024","journal-title":"Proteomes"},{"issue":"08","key":"10.1055\/s-0044-1791734_bib30","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/IGC.0b013e31826bd1f2","article-title":"Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report","volume":"22","author":"Modugno","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1055\/s-0044-1791734_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1757-2215-3-8","article-title":"The detection, treatment, and biology of epithelial ovarian cancer","volume":"3","author":"Gubbels","year":"2010","journal-title":"J Ovarian Res"},{"issue":"07","key":"10.1055\/s-0044-1791734_bib32","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1002\/jcp.27926","article-title":"Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments","volume":"234","author":"Zheng","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1055\/s-0044-1791734_bib33","doi-asserted-by":"crossref","first-page":"1179299","DOI":"10.1177\/1179299X19860815","article-title":"Chemotherapy resistance in advanced ovarian cancer patients","volume":"11","author":"Pokhriyal","year":"2019","journal-title":"Biomark Cancer"},{"key":"10.1055\/s-0044-1791734_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"21","key":"10.1055\/s-0044-1791734_bib35","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"issue":"02","key":"10.1055\/s-0044-1791734_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10549-020-06054-x","article-title":"Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-\/PR-breast cancer cells","volume":"186","author":"Tzekaki","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"09","key":"10.1055\/s-0044-1791734_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092125","article-title":"Therapeutic strategies focused on cancer-associated hypercoagulation for ovarian clear cell carcinoma","volume":"14","author":"Tamura","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1055\/s-0044-1791734_bib38","article-title":"The role of cancer-associated mesothelial cells in the progression and therapy of ovarian cancer","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1055\/s-0044-1791734_bib39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"01","key":"10.1055\/s-0044-1791734_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/gyno.2000.5931","article-title":"Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells","volume":"79","author":"Huang","year":"2000","journal-title":"Gynecol Oncol"}],"container-title":["Global Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2699940425000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2699940425000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:36:11Z","timestamp":1761204971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2699940425000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2699940425000360"],"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791734","relation":{},"ISSN":["2699-9404"],"issn-type":[{"value":"2699-9404","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of the Plasminogen Activator Inhibitor 1 (PAI1) in Ovarian Cancer: Mechanisms and Therapeutic Implications","name":"articletitle","label":"Article Title"},{"value":"Global Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1055\/s-0044-1791734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 International Knowledge Direct Medical Associations. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}